OCUL
Live chart
What they do
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
For information only · Important disclosures
Grades vs sector
No sector grades for OCUL yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Systematic Models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-03 | -0.39 | -0.35 | +9.4% |
| 2026-05-05 | -0.31 | -0.40 | -27.6% |
| 2026-02-05 | -0.34 | -0.29 | +13.9% |
| 2025-11-04 | -0.35 | -0.38 | -9.6% |
| 2025-08-05 | -0.35 | -0.39 | -10.7% |
| 2025-05-05 | -0.28 | -0.37 | -33.0% |
| 2025-03-03 | -0.22 | -0.29 | -31.8% |
| 2024-11-14 | -0.21 | -0.22 | -6.5% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $13.5M | +0.1% |
| 2026-03-31 | $10.8M | – |
| 2025-12-31 | $13.2M | – |
| 2025-09-30 | $14.5M | – |
| 2025-06-30 | $13.5M | – |
Rating changes
Third-party analyst actions, not Coteau's views. All rating changes
Insider trades
$87.4K
$76.6K
$70.4K
$11.3K
$233.2K
$35.5K
$20.4K
$32.7K
Stats refreshed 2026-10-21 18:23:22 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Beta 0.9 · Oct 21, 2026